IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Aratana Therapeutics, Inc. (“Aratana” or the “Company”) (Nasdaq: PETX) concerning possible violations of federal securities laws.
If you purchased shares of Aratana and want more information free of charge, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: 949-419-3834, or by e-mail at email@example.com.
On February 6, 2017, Aratana announced that the Center for Veterinary Medicine (“CVM”) had asked for more information about ENTYCE, its appetite stimulation drug. Aratana informed investors that it “now anticipates that ENTYCE … will be commercially available by late 2017” and that the CVM's demand was “in connection with the Company's post-approval supplement request to transfer the manufacturing of ENTYCE to a new vendor in order to produce ENTYCE at a commercial scale.” When this information was released to the public, the value of Aratana stock fell, causing investors severe harm.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: 949-419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.